GlassScriptPhysician profile
Vera Kandror Denmark
NPI 1609071273
$1,359.94
in general payments reported to CMS, 2019-2025
11 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $37.55 · 2021: $42.27 · 2022: $284 · 2023: $281 · 2024: $252 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.81 |
| Education | $152.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $393.22 | 2021-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.00 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $223.45 | 2019-2025 | Tremfya |
| Pfizer INC. | $164.81 | 2024 | |
| Ferring Pharmaceuticals INC. | $71.27 | 2019-2022 | |
| Genzyme Corporation | $62.31 | 2023 | |
| Celgene Corporation | $50.55 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $45.19 | 2025 | Voquezna |
| Gilead Sciences, INC. | $26.86 | 2025 | |
| Ardelyx, INC. | $22.96 | 2024 | Ibsrela |
| Organon LLC | $17.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Denmark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.